160 related articles for article (PubMed ID: 1974826)
21. Prostaglandin E2 from macrophages of murine splenocyte cultures inhibits the generation of lymphokine-activated killer cell activity.
Ohnishi H; Lin TH; Nakajima I; Chu TM
Tumour Biol; 1991; 12(2):99-110. PubMed ID: 2028183
[TBL] [Abstract][Full Text] [Related]
22. Induction of murine lymphokine-activated killer cells by recombinant IL-7.
Lynch DH; Miller RE
J Immunol; 1990 Sep; 145(6):1983-90. PubMed ID: 1975262
[TBL] [Abstract][Full Text] [Related]
23. Elevated prostaglandin E2 production by monocytes is responsible for the depressed levels of natural killer and lymphokine-activated killer cell function in patients with breast cancer.
Baxevanis CN; Reclos GJ; Gritzapis AD; Dedousis GV; Missitzis I; Papamichail M
Cancer; 1993 Jul; 72(2):491-501. PubMed ID: 8319179
[TBL] [Abstract][Full Text] [Related]
24. Th2-like response and antitumor effect of anti-interleukin-4 mAb in mice bearing renal cell carcinoma.
Takeuchi T; Ueki T; Sasaki Y; Kajiwara T; Li B; Moriyama N; Kawabe K
Cancer Immunol Immunother; 1997 Jan; 43(6):375-81. PubMed ID: 9067410
[TBL] [Abstract][Full Text] [Related]
25. [Effect of biological response modifiers on a spontaneous murine renal cell carcinoma regression of metastases caused by the streptococcal preparation OK-432].
Tanji S
Nihon Hinyokika Gakkai Zasshi; 1991 May; 82(5):716-25. PubMed ID: 1875566
[TBL] [Abstract][Full Text] [Related]
26. Molecular mechanisms of immune-mediated lysis of murine renal cancer: differential contributions of perforin-dependent versus Fas-mediated pathways in lysis by NK and T cells.
Sayers TJ; Brooks AD; Lee JK; Fenton RG; Komschlies KL; Wigginton JM; Winkler-Pickett R; Wiltrout RH
J Immunol; 1998 Oct; 161(8):3957-65. PubMed ID: 9780164
[TBL] [Abstract][Full Text] [Related]
27. Killing of Fas ligand-resistant renal carcioma cells by interleukin-2- and BCG-activated effector cells.
Brandau S; Suttmann H; Flad HD; Jocham D; Böhle A
Cancer Immunol Immunother; 2000 Sep; 49(7):369-76. PubMed ID: 10999463
[TBL] [Abstract][Full Text] [Related]
28. Local tumor irradiation augments the response to IL-2 therapy in a murine renal adenocarcinoma.
Younes E; Haas GP; Dezso B; Ali E; Maughan RL; Kukuruga MA; Montecillo E; Pontes JE; Hillman GG
Cell Immunol; 1995 Oct; 165(2):243-51. PubMed ID: 7553889
[TBL] [Abstract][Full Text] [Related]
29. In vivo boosting of lung natural killer and lymphokine-activated killer cell activity by interleukin-2: comparison of systemic, intrapleural and inhalation routes.
Flexman JP; Manning LS; Robinson BW
Clin Exp Immunol; 1990 Oct; 82(1):151-6. PubMed ID: 2208789
[TBL] [Abstract][Full Text] [Related]
30. Tumor-specific CTL kill murine renal cancer cells using both perforin and Fas ligand-mediated lysis in vitro, but cause tumor regression in vivo in the absence of perforin.
Seki N; Brooks AD; Carter CR; Back TC; Parsoneault EM; Smyth MJ; Wiltrout RH; Sayers TJ
J Immunol; 2002 Apr; 168(7):3484-92. PubMed ID: 11907109
[TBL] [Abstract][Full Text] [Related]
31. Lymphokine-activated killer cells and aging in mice: significance for defining the precursor cell.
Kawakami K; Bloom ET
Mech Ageing Dev; 1987 Dec; 41(3):229-40. PubMed ID: 2892985
[TBL] [Abstract][Full Text] [Related]
32. Endogenous and adoptively transferred A-NK and T-LAK cells continuously accumulate within murine metastases up to 48 h after inoculation.
Hokland M; Kjaergaard J; Kuppen PJ; Nannmark U; Agger R; Hokland P; Basse P
In Vivo; 1999; 13(3):199-204. PubMed ID: 10459491
[TBL] [Abstract][Full Text] [Related]
33. Inhibition of murine lymphokine-activated killer (LAK) cell activity by adherent cells.
Longley RE; Stewart D; Roe KG; Good RA
Cell Immunol; 1989 Jul; 121(2):225-36. PubMed ID: 2786756
[TBL] [Abstract][Full Text] [Related]
34. Retaliation against tumor cells showing aberrant HLA expression using lymphokine activated killer-derived T cells.
Falk CS; Noessner E; Weiss EH; Schendel DJ
Cancer Res; 2002 Jan; 62(2):480-7. PubMed ID: 11809699
[TBL] [Abstract][Full Text] [Related]
35. Effects of stimulating interleukin -2/anti- interleukin -2 antibody complexes on renal cell carcinoma.
Han KH; Kim KW; Yan JJ; Lee JG; Lee EM; Han M; Cho EJ; Kang SS; Lim HJ; Koo TY; Ahn C; Yang J
BMC Urol; 2016 Jan; 16():2. PubMed ID: 26772545
[TBL] [Abstract][Full Text] [Related]
36. Potentiation of a dendritic cell vaccine for murine renal cell carcinoma by CpG oligonucleotides.
Chagnon F; Tanguay S; Ozdal OL; Guan M; Ozen ZZ; Ripeau JS; Chevrette M; Elhilali MM; Thompson-Snipes LA
Clin Cancer Res; 2005 Feb; 11(3):1302-11. PubMed ID: 15709202
[TBL] [Abstract][Full Text] [Related]
37. Generation of activated killer cells in tumor-bearing hosts.
Ting CC; Hargrove ME; Stephany D
Int J Cancer; 1987 Feb; 39(2):232-9. PubMed ID: 3100459
[TBL] [Abstract][Full Text] [Related]
38. Identification of a novel CD56- lymphokine-activated killer cell precursor in cancer patients receiving recombinant interleukin 2.
McKenzie RS; Simms PE; Helfrich BA; Fisher RI; Ellis TM
Cancer Res; 1992 Nov; 52(22):6318-22. PubMed ID: 1384959
[TBL] [Abstract][Full Text] [Related]
39. Inhibition of murine renal carcinoma pulmonary metastases by systemic administration of interferon gamma: mechanism of action and potential for combination with interleukin 4.
Hillman GG; Younes E; Visscher D; Hamzavi F; Kim S; Lam JS; Montecillo EJ; Ali E; Pontes JE; Puri RK; Haas GP
Clin Cancer Res; 1997 Oct; 3(10):1799-806. PubMed ID: 9815566
[TBL] [Abstract][Full Text] [Related]
40. Suppression of hepatic lymphokine-activated killer cell induction by murine Kupffer cells and hepatocytes.
Tzung SP; Gaines KC; Lance P; Ehrke MJ; Cohen SA
Hepatology; 1990 Oct; 12(4 Pt 1):644-52. PubMed ID: 2210667
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
